匯盈控股(00821.HK):認購初步認購股份認購協議失效
格隆匯1月3日丨匯盈控股(00821.HK)發佈公告,有關公司與認購人Macarthur Court Acquisition Corp.訂立認購協議,據此,認購人擬認購公司發行的9900萬港元的初步認購股份;及授出選擇權在初步完成日期起計1年內進一步認購3600萬港元的認購股份及本金總額9900萬港元的可換股債券,但並無責任作出認購。
根據認購協議,認購協議須待其先決條件於最後完成日期或之前達成或豁免後,方告完成。隨後,公司與認購人協定將最後完成日期延後至2019年12月31日。於該公佈日期,認購協議已經失效及不再具有任何作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.